News

Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis

01/22/2024

Jordan Kadish

Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.

Ruxolitinib treatment...

01/22/2024

Oncology

News

Ropeginterferon Alfa-2B Demonstrates Efficacy Among High-Risk Patients With Philadelphia-Negative Myeloproliferative Neoplasms

01/22/2024

Jordan Kadish

A retrospective observational study showed that ropeginterferon alfa-2b demonstrated efficacy among high-risk patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

A retrospective observational...

01/22/2024

Oncology

News

Pelabresib Plus Ruxolitinib Shows Clinical Benefit Among JAK-Naïve Patients With Myelofibrosis

01/05/2024

Jordan Kadish

Results from the phase 3 MANIFEST-2 study demonstrated that combining pelabresib and ruxolitinib yielded clinical activity among patients with JAK-naïve myelofibrosis.

Results from the phase 3...

01/05/2024

Oncology

News

Inflammatory Comorbidities as Prognostic Factors Among Younger Patients With Myelofibrosis

01/05/2024

Jordan Kadish

Retrospective analysis findings indicated that inflammatory comorbidities were correlated with progression of disease risk among younger patients with myelofibrosis.

Retrospective analysis findings...

01/05/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Conference Coverage

Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV

12/21/2023

Featuring Claire Harrison, MD, FRCP

Featuring Claire Harrison, MD, FRCP ...

At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Pankit Vachhani, MD, O’Neal Comprehensive Cancer Center

Conference Coverage

Platelet Count Response Among Patients With Cytopenic Myelofibrosis Treated With Pacritinib

12/21/2023

Featuring Pankit Vachhani, MD

At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

News

Ruxolitinib Exhibits Safety, Efficacy Among Elderly Patients With Therapy-Naïve Myelofibrosis

11/20/2023

Amber Denham

Real-world results from a phase 4 study demonstrate that among elderly patients with therapy-naïve myelofibrosis, ruxolitinib treatment yielded safety and efficacy.

Real-world results from a phase...

11/20/2023

Oncology

News

Momelotinib Yields Substantial Symptom Benefits Among Patients With Myelofibrosis

11/08/2023

Amber Denham

Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF).

Patient-reported outcomes from...

11/08/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology